Filing summary: Eyenovia, Inc. Form 10-K
Entity and period: The request identifies HYPERION DEFI, INC., but the supplied filing is Eyenovia, Inc.’s Form 10-K for the fiscal year ended December 31, 2021, filed March 30, 2022. The figures below summarize Eyenovia, not Hyperion DeFi. The filing reports annual results; it does not provide a clear standalone 2021 fourth-quarter financial summary.
Business context
Eyenovia is a clinical-stage ophthalmic company developing drug-device combination products using its microdose array print (MAP) platform and Optejet dispenser. Its three main candidates are Mydcombi for pupil dilation, MicroLine for presbyopia, and MicroPine for pediatric progressive myopia. It had no approved products, product-sales revenue, or recurring revenue at year-end.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $14.0 million | $2.0 million |
| Cost of revenue | $1.6 million | $0.8 million |
| Gross profit | $12.4 million | $1.2 million |
| Research and development | $14.5 million | $13.4 million |
| General and administrative | $10.8 million | $7.6 million |
| Operating loss | $12.9 million | $19.8 million |
| Net loss | $12.8 million | $19.8 million |
| Basic and diluted loss per share | $0.49 | $0.94 |
| Net cash used in operating activities | $20.9 million | $6.4 million |
Revenue was chiefly license-related, not product sales: 2021 included recognition of the $10.0 million Bausch upfront fee and $4.0 million of Arctic Vision upfront fees. The reported gross margin was approximately 89% in 2021 versus 60% in 2020, but it reflects licensing revenue and should not be read as a commercial product margin.
At December 31, 2021, cash and cash equivalents were $19.5 million, with another $7.875 million classified as restricted cash pledged under the SVB loan arrangement. Working capital was $10.8 million, down from $15.2 million. Gross notes payable were $7.5 million; the balance sheet carried the loan net of discount at $7.15 million, classified as current. The SVB loan was callable by the bank because Mydcombi had not received FDA approval. The company reported an accumulated deficit of $90.2 million.
Changes, outlook and material items
- Revenue increased from $2.0 million to $14.0 million primarily as previously deferred license fees became earned and recognizable. Net loss narrowed, while operating cash use increased substantially.
- In October 2021, the FDA issued a Complete Response Letter for Mydcombi. The filing says the FDA required additional non-clinical device information following reclassification of the dispenser as a distinct device constituent of a drug-device combination product. Eyenovia expected to resubmit the NDA in Q3 2022.
- Management anticipated VISION-2 top-line results for MicroLine in mid-2022 and full enrollment in the Bausch-sponsored CHAPERONE MicroPine study in Q4 2022. These are forward-looking expectations, not achieved results.
- Bausch licensed MicroPine in the United States and Canada; potential additional milestone payments total up to $35.0 million. Arctic Vision licensed the three candidates in Greater China and South Korea; potential additional payments total up to $43.75 million. These amounts are contingent and not assured revenue.
- The company reported substantial doubt about its ability to continue as a going concern for at least one year from issuance of the financial statements, absent additional funding or sufficient recurring revenue. The auditor’s report includes a going-concern explanatory paragraph.
- After year-end, Eyenovia reported approximately $15 million of gross proceeds from a March 2022 share-and-warrant offering and approximately $0.9 million from an at-the-market offering. These financings provide additional cash but involve potential dilution.
- Other risks highlighted include clinical and regulatory uncertainty, supplier and COVID-19-related delays, reliance on third parties, competition (including Allergan’s Vuity for presbyopia), and the need for further capital. Management said disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- Confirm the issuer: the supplied 10-K is Eyenovia’s, not HYPERION DEFI, INC.’s.
- Track unrestricted cash, the restricted SVB collateral, the loan’s callable status, and the timing and terms of any further financing.
- Check the status and actual outcome of the Mydcombi NDA resubmission and FDA review; the Q3 2022 filing target was management’s expectation.
- Verify clinical-trial milestones and final results for VISION-2 and CHAPERONE, rather than relying on interim or projected dates.
- Assess whether contingent license milestones, royalties, and commercialization plans translate into recurring cash revenue; the 2021 revenue was primarily licensing-related, and the company had no product sales.